Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is a funding call from National Institutes of Health that closes 05 November 2027. Funding: Up to $1,500,000 direct costs per year. Eligibility: NIH-style eligibility: US institutions only; non-US (foreign) organisations are not eligible to apply.
- Funder
- National Institutes of Health
- Deadline
- 05 Nov 2027 (386 days)
- Amount
- Up to $1,500,000 direct costs per year
- Region / eligibility
- United States
- Career stage
- established / PI
- Fields
- chemistry, pharma process
- Reference
- PAR-25-297
- Official call
- Grants.gov listing · Program page
Eligibility in plain language
NIH-style eligibility: US institutions only; non-US (foreign) organisations are not eligible to apply.
Who should apply
Synthetic, physical and analytical chemists, medicinal chemists and pharma process / drug-development teams — best fit for PIs and research groups.
Summary from source
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development …